{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:58:12Z","timestamp":1793347092402,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NeoTract Inc., Teleflex"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a need to understand the predictors of prostatic urethral lift (PUL) durability to help physicians counsel patients and optimize outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A simple logistic regression analysis was performed on a pooled dataset of 331 subjects across 5 PUL controlled studies with up to 5 years follow up. Predictors of \u201csurgical durability\u201d (no surgical treatment for return of symptoms) and \u201ctotal durability\u201d (no surgical or medical treatment for return of symptoms) were assessed at 1- and 5-year post-procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Placing \u22644 implants regardless of baseline prostate volume was associated with increased surgical retreatment within the first year. Through one year, more implants were protective of retreatment; for every incremental implant placed, surgical retreatment odds decreased an additional 41.2% and risk of combined surgical or medical retreatment decreased 30.2%. Higher implant density was also protective through one year; for each additional implant placed per 10cc prostate volume, surgical retreatment odds decreased incrementally by 79.0%. Up to 5 years, a higher baseline pretreatment IPSS score predicted higher rates of surgical or medical retreatment; for every one-point score increase of baseline IPSS, surgical or medical retreatment odds increased 5.2%. Baseline demographics, medical history and baseline sexual function were not predictors of surgical or total durability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More implants, higher implant density, and lower baseline IPSS are all associated with decreased surgical and medical retreatment rates up to 5 years following PUL. These findings inform optimizing PUL technique, considering earlier intervention and counseling men on outcomes prior to PUL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01101-y","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:40:29Z","timestamp":1778049629000},"page":"836-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of durability of the prostatic urethral lift (PUL) for benign prostatic hyperplasia"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-5591","authenticated-orcid":false,"given":"Gregg","family":"Eure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Rukstalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1101_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211:11\u201319.","journal-title":"J Urol"},{"key":"1101_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JU.0000000000002184","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Kumar Das A, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-surgical evaluation and treatment. J Urol. 2021;206:818\u201326.","journal-title":"J Urol"},{"key":"1101_CR3","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802\u201313.","journal-title":"Can J Urol"},{"key":"1101_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767\u201375.","journal-title":"BJU Int"},{"key":"1101_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/end.2019.0167","volume":"33","author":"G Eure","year":"2019","unstructured":"Eure G, Gange S, Walter P, Khan A, Chabert C, Mueller T, et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol. 2019;33:576\u201384.","journal-title":"J Endourol"},{"key":"1101_CR6","first-page":"7094","volume":"21","author":"N Shore","year":"2014","unstructured":"Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol. 2014;21:7094\u2013101.","journal-title":"Can J Urol"},{"key":"1101_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bju.13666","volume":"118","author":"D Rukstalis","year":"2016","unstructured":"Rukstalis D, Rashid P, Bogache WK, Tutrone RF, Barkin J, Chin PT, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int. 2016;118:14\u201322.","journal-title":"BJU Int"},{"key":"1101_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-018-0118-x","volume":"22","author":"D Rukstalis","year":"2019","unstructured":"Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 2019;22:411\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1101_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41391-023-00741-8","volume":"27","author":"S Kaplan","year":"2024","unstructured":"Kaplan S, Kaufman RP Jr, Mueller T, Elterman D, Chughtai B, et al. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis. 2024;27:485\u201391.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1101_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41391-021-00434-0","volume":"25","author":"CG Roehrborn","year":"2022","unstructured":"Roehrborn CG, Chin PT, Woo HH. The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis. 2022;25:79\u201385.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1101_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","volume":"160","author":"RC Flanigan","year":"1998","unstructured":"Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998;160:12\u20136.","journal-title":"J Urol"},{"key":"1101_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00002512-200320030-00003","volume":"20","author":"A Tubaro","year":"2003","unstructured":"Tubaro A, Carter S, Trucchi A, Punzo G, Petta S, Miano L. Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage. Drugs Aging. 2003;20:185\u201395.","journal-title":"Drugs Aging"},{"key":"1101_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.eururo.2006.07.050","volume":"51","author":"V Mirone","year":"2007","unstructured":"Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007;51:57\u201366.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01101-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:24Z","timestamp":1790719224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01101-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01101-y","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GE, MA, DBR, PC, NB, and CR are paid consultants for NeoTract\/Teleflex, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All included clinical trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Each study received approval from the appropriate institutional review board or independent ethics committee at every participating site, and all participants provided written informed consent prior to enrollment. The present study is a pooled analysis of de-identified data from these completed trials and did not require additional ethics committee approval.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}